229 related articles for article (PubMed ID: 2512141)
1. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):917-9. PubMed ID: 2512141
[TBL] [Abstract][Full Text] [Related]
2. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains.
Bantar C; Di Chiara M; Nicola F; Relloso S; Smayevsky J
Diagn Microbiol Infect Dis; 2000 May; 37(1):41-4. PubMed ID: 10794939
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of cefepime against nosocomial isolates.
Sofianou D; Tsoulfa S; Kontodimou L; Polydorou F; Malaka E
J Chemother; 1997 Oct; 9(5):341-6. PubMed ID: 9373789
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus other beta-lactams against multiresistant gram-negative isolates.
Giamarellou H; Sahin A; Chryssouli Z
Drugs Exp Clin Res; 1987; 13(3):149-53. PubMed ID: 3622243
[TBL] [Abstract][Full Text] [Related]
6. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
Tumah H
Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
[TBL] [Abstract][Full Text] [Related]
7. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
Watanabe N; Hiruma R; Katsu K
J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa.
Chen YH; Peng CF; Lu PL; Tsai JJ; Chen TP
Kaohsiung J Med Sci; 2004 Jun; 20(6):261-7. PubMed ID: 15253466
[TBL] [Abstract][Full Text] [Related]
9. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
[TBL] [Abstract][Full Text] [Related]
11. Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.
Fung-Tomc J; Huczko E; Pearce M; Kessler RE
Antimicrob Agents Chemother; 1988 Sep; 32(9):1443-5. PubMed ID: 3143306
[TBL] [Abstract][Full Text] [Related]
12. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
Wang H; Chen MJ;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
[TBL] [Abstract][Full Text] [Related]
13. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams.
Bonfiglio G; Marchetti F
Chemotherapy; 2000; 46(4):229-34. PubMed ID: 10859428
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial resistance of Pseudomonas aeruginosa strains isolated from surgical infections in a 7-year period at a general hospital in Venezuela.
Rodriguez CN; Rodriguez-Morales AJ; Garcia A; Pastran B; Meijomil P
Surg Infect (Larchmt); 2006 Jun; 7(3):269-73. PubMed ID: 16875460
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials.
Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():143-7. PubMed ID: 2509412
[TBL] [Abstract][Full Text] [Related]
17. [E-test to study small inhibitor concentrations, bacterial diversity and to identify presumptively beta-lactamases in strains of Pseudomonas aeruginosa and Acinetobacter baumannii associated with +nosocomial infections].
Triantafilo V; Fica A; Silva M; Thompson L
Rev Med Chil; 1997 Feb; 125(2):149-60. PubMed ID: 9430934
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of BRL 36650, a new penicillin.
Van Landuyt HW; Lambert A; Boelaert J; Gordts B
Antimicrob Agents Chemother; 1986 Feb; 29(2):362-6. PubMed ID: 3087281
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Christenson JC; Korgenski EK; Daly JA
J Antimicrob Chemother; 2000 Jun; 45(6):899-901. PubMed ID: 10837448
[TBL] [Abstract][Full Text] [Related]
20.
Pahlavanzadeh F; Kalantar-Neyestanaki D; Motamedifar M; Mansouri S
Yale J Biol Med; 2020 Mar; 93(1):29-34. PubMed ID: 32226332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
